ASCO GU 2014: Will Galeterone make it to market in Prostate Cancer?
San Francisco – Tokai Pharmaceuticals is a case study in how not to do drug development.
A company, founded in 2004, with a novel prostate cancer drug has taken 10 years to make it to phase II drug development while competitors such as Medivation and Johnson & Johnson have brought similar new drugs to market in multiple prostate cancer indications.
At ASCO GU this week (Abstract 71), Tokai reported part 1 of their phase 2 ARMOR2 trial with reformulated galeterone (TOK-001) in men with prostate cancer at various stages of the disease in a poster. Part 2 of the study will enrol 136 patients with a once daily dose of 2550 mg.
To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content.
This content is restricted to subscribers
